These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28851171)

  • 41. Low-dose human chorionic gonadotropin versus estradiol/progesterone luteal phase support in gonadotropin-releasing hormone agonist-triggered assisted reproductive technique cycles: understanding a new approach.
    Garcia-Velasco JA; Motta L; López A; Mayoral M; Cerrillo M; Pacheco A
    Fertil Steril; 2010 Dec; 94(7):2820-3. PubMed ID: 20673892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Luteal phase serum progesterone levels after GnRH-agonist trigger - how low is still high enough for an ongoing pregnancy?
    Lawrenz B; Samir S; Melado L; Ruiz F; Fatemi HM
    Gynecol Endocrinol; 2018 Mar; 34(3):195-198. PubMed ID: 29037085
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibitory effects of a gonadotropin-releasing hormone agonist on the luteal synthesis of progesterone, estradiol receptors, and prolactin surges during early pregnancy.
    Sridaran R; Ghose M; Mahesh VB
    Endocrinology; 1988 Oct; 123(4):1740-6. PubMed ID: 3046924
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
    Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
    Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function.
    DiLuigi AJ; Nulsen JC
    Curr Opin Obstet Gynecol; 2007 Jun; 19(3):258-65. PubMed ID: 17495643
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Variable tolerance of the developing follicle and corpus luteum to gonadotropin-releasing hormone antagonist-induced gonadotropin withdrawal in the human.
    Hall JE; Bhatta N; Adams JM; Rivier JE; Vale WW; Crowley WF
    J Clin Endocrinol Metab; 1991 May; 72(5):993-1000. PubMed ID: 1902489
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Luteal phase support with estradiol and progesterone versus progesterone alone in GnRH antagonist ICSI cycles: a randomized controlled study.
    Ismail Madkour WA; Noah B; Abdel Hamid AM; Zaheer H; Al-Bahr A; Shaeer M; Moawad A
    Hum Fertil (Camb); 2016 Jun; 19(2):142-9. PubMed ID: 27434094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effect of luteal-phase gonadotropin-releasing hormone agonist administration on pregnancy outcome in IVF/ICSI cycles: a systematic review and Meta-analysis].
    Yu LP; Liu N; Liu Y
    Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):850-858. PubMed ID: 27916070
    [No Abstract]   [Full Text] [Related]  

  • 50. Growth Hormone Supplementation in the Luteal Phase Before Microdose GnRH Agonist Flare Protocol for In Vitro Fertilization.
    Dunne C; Seethram K; Roberts J
    J Obstet Gynaecol Can; 2015 Sep; 37(9):810-815. PubMed ID: 26605451
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Luteal responses to gonadotropin-releasing hormone during the luteal phase: relation to the age of corpus luteum.
    Caruso A; Lanzone A; Fulghesu AM; Mancuso S
    J Clin Endocrinol Metab; 1987 Feb; 64(2):274-8. PubMed ID: 3098770
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Luteal phase support in ART treatments.
    Or Y; Vaisbuch E; Shoham Z
    Methods Mol Biol; 2014; 1154():251-60. PubMed ID: 24782012
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The presence of pinopodes in the human endometrium does not delineate the implantation window.
    Quinn C; Ryan E; Claessens EA; Greenblatt E; Hawrylyshyn P; Cruickshank B; Hannam T; Dunk C; Casper RF
    Fertil Steril; 2007 May; 87(5):1015-21. PubMed ID: 17224147
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Disturbances of the endometrium in the luteal phase of cycles stimulated for in vitro fertilization and of normal cycles treated with vaginal progesterone.
    Kresanov I; Nikkanen V; Klemi P
    Ann Chir Gynaecol Suppl; 1994; 208():33-9. PubMed ID: 8092768
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Further characterization of the luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles.
    Balasch J; Fábregues F; Tur R; Creus M; Casamitjana R; Peñarrubia J; Barri PN; Vanrell JA
    Hum Reprod; 1995 Jun; 10(6):1377-81. PubMed ID: 7593500
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin for triggering follicular maturation in in vitro fertilization.
    Segal S; Casper RF
    Fertil Steril; 1992 Jun; 57(6):1254-8. PubMed ID: 1601147
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Corpus luteum insufficiency induced by a rapid gonadotropin-releasing hormone-induced gonadotropin secretion pattern in the follicular phase.
    Soules MR; Clifton DK; Bremner WJ; Steiner RA
    J Clin Endocrinol Metab; 1987 Sep; 65(3):457-64. PubMed ID: 3114301
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Luteal phase support with GnRH-a improves implantation and pregnancy rates in IVF cycles with endometrium of Qublan H; Amarin Z; Al-Qudah M; Diab F; Nawasreh M; Malkawi S; Balawneh M
    Hum Fertil (Camb); 2008 Mar; 11(1):43-7. PubMed ID: 18320439
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Controlled ovarian hyperstimulation for in vitro fertilization alters endometrial receptivity in humans: protocol effects.
    Haouzi D; Assou S; Dechanet C; Anahory T; Dechaud H; De Vos J; Hamamah S
    Biol Reprod; 2010 Apr; 82(4):679-86. PubMed ID: 20042535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.